Table 1.

Patient Characteristics

Age (years)
Median	52
Range	19 – 76
Gender
Male	17 (68)
Female	8 (32)
KPS
90–100	13 (52)
80	10 (40)
70	2 (8)
Time from Diagnosis (weeks)
Median	58.1
Range	29.9–260.9
EIAED
Yes	1 (4)
No	24 (96)
Corticosteroids
Yes	10 (40)
Average Dose (mg/day)	2.8
Range (mg/day)	0–16
No	15 (60)
Surgery Prior to Enrollment
None	22 (88)
Biopsy	2 (8)
STR	1 (4)
Number Prior PD
1	11 (44)
2	13 (52)
3	1 (4)
Progression on BV at Enrollment
No	2 (8)
Yes	23 (92)
BV Partner at Prior Progression
None	9 (36)
Chemotherapy	15 (60)
Etoposide	2
Temozolomide	13
Sorafenib	1 (4)
Number Prior BV PD
1	24 (96)
2	1 (4)
Number months on prior BV
Median	9
Range	2–34

Abbreviations: BV, bevacizumab; EIAED, CYP3A enzyme inducing anti-epileptic drugs; KPS, Karnofsky performance status; mg, milligram; PD, progressive disease; STR, subtotal resection